Medicenna Synthetic Control Arm Success Story

Key takeaways:

  • In Phase 2, the SCA enabled Medicenna to better understand the expected survival benefit for their treatment. This knowledge supported their proposed hybrid Phase 3 design.
  • In a precedent-setting regulatory decision, the FDA agreed to consider the use of a hybrid SCA in Medicenna’s Phase 3 registrational trial.

Download the case study to learn more.

Request Free!